Real-World Patient Eligibility for Alzheimer's Disease Anti-Amyloid Therapy in Seven Swedish Memory Clinics.

Anna Rosenberg; Anna Rennie; Urban Ekman; Makrina Daniilidou; Anette Hall; Anna Matton; Ari Solomon; Lars-Olof Wahlund; Miia Kivipelto; Eric Westman

doi:10.1111/ene.70786

SCHEDA SCIENTIFICA2026Altra ricerca

Real-World Patient Eligibility for Alzheimer's Disease Anti-Amyloid Therapy in Seven Swedish Memory Clinics.

Anna Rosenberg, Anna Rennie, Urban Ekman, Makrina Daniilidou, Anette Hall, Anna Matton, Ari Solomon, Lars-Olof Wahlund, Miia Kivipelto, Eric Westman

European journal of neurology · 2026

Psicologia clinica Psicoterapia Psicologia cognitiva

Abstract e pubblicazione originale

L’abstract è consultabile nella fonte originale. Non viene ripubblicato qui perché non risulta verificata una licenza compatibile.

Leggi nella fonte originale ↗

Parole chiave

HumansAlzheimer DiseaseSwedenFemaleMaleAgedAmyloid beta-PeptidesAged, 80 and overCognitive DysfunctionEligibility DeterminationCohort StudiesAlzheimer's diseaseanti‐amyloid therapydonanemabeligibilitylecanemab

Come citare questo studio

Anna Rosenberg, Anna Rennie, Urban Ekman, Makrina Daniilidou, Anette Hall, Anna Matton, Ari Solomon, Lars-Olof Wahlund, Miia Kivipelto, Eric Westman. (2026). Real-World Patient Eligibility for Alzheimer's Disease Anti-Amyloid Therapy in Seven Swedish Memory Clinics.. European journal of neurology. DOI: 10.1111/ene.70786

Consulta la pubblicazione originale ↗